Skip to main content
Erschienen in: European Journal of Pediatrics 12/2006

01.12.2006 | Original Paper

Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids

verfasst von: Anna M. Wasilewska, Walentyna M. Zoch-Zwierz, Mirosława Pietruczuk

Erschienen in: European Journal of Pediatrics | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glucocorticoids are still the mainstay of therapy for nephrotic syndrome (NS) in children. Poor response to glucocorticoids may relate, in part, to the overexpression of P-glycoprotein (P-gp). The aim of the present study was to determine the expression of P-gp in lymphocytes (CD3) in the peripheral blood of children with steroid-sensitive nephrotic syndrome in the dynamics of the disease. The study group (I) consisted of 18 children, median age 5.75 years, with steroid-sensitive nephrotic syndrome, in whom the examinations were carried out three times: (A) before treatment, during relapse; (B) after 3–4 weeks of prednisone treatment; (C) 2 months after finishing prednisone treatment. The control group (II) consisted of 18 healthy children of the same age. P-gp expression in CD3 lymphocytes of peripheral blood was measured using flow cytometry. During NS relapse and prior to glucocorticoid administration, the CD3/P-gp level was higher (median 3.20%, range 0.80–7.80%) when compared to healthy controls (1.10%, range 0.30– 2.20%) (p<0.01). During glucocorticoid treatment, CD3/P-gp increased significantly and was much higher than in the control group (p<0.01) and in the NS children before treatment (p<0.01). In remission, the P-gp expression decreased, but did not achieve the values of the controls (p<0.05). Fourteen out of eighteen (14/18) children still showed P-gp values above the cut-off level. We also found a positive correlation between the P-gp expression and total prednisone dose in the NS children in all examinations: A: (r=0.540, p<0.05); B: (r=0.630, p<0.01); C: (r=0.653, p<0.01).

Conclusion

In conclusion, the overexpression of P-gp in remission, after finishing glucocorticoid treatment, may indicate that P-gp plays a role in the response to corticosteroids in nephrotic children.
Literatur
1.
Zurück zum Zitat Aicardi G, Benso L, Vignolo M, Terragna A, Verrina E, Cordone G, Coppo R, Sernia O, Sardella ML, Di Battista E (1993) Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. Br J Rheumatol 32(Suppl 2):39–43PubMed Aicardi G, Benso L, Vignolo M, Terragna A, Verrina E, Cordone G, Coppo R, Sernia O, Sardella ML, Di Battista E (1993) Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. Br J Rheumatol 32(Suppl 2):39–43PubMed
2.
Zurück zum Zitat Bourgeois S, Gruol DJ, Newby RF, Rajah FM (1993) Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 7(7):840–851PubMedCrossRef Bourgeois S, Gruol DJ, Newby RF, Rajah FM (1993) Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 7(7):840–851PubMedCrossRef
3.
Zurück zum Zitat Clark AG, Barratt TM (1998) Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams & Wilkins, Baltimore, Maryland, pp 731–747 Clark AG, Barratt TM (1998) Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams & Wilkins, Baltimore, Maryland, pp 731–747
4.
Zurück zum Zitat Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 67(1):40–48PubMed Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 67(1):40–48PubMed
5.
Zurück zum Zitat Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88(5):1747–1754PubMed Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88(5):1747–1754PubMed
6.
Zurück zum Zitat Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr 152(4):357–361PubMedCrossRef Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr 152(4):357–361PubMedCrossRef
7.
Zurück zum Zitat Farrell RJ, Kelleher D (2003) Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178(3):339–346PubMedCrossRef Farrell RJ, Kelleher D (2003) Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178(3):339–346PubMedCrossRef
8.
Zurück zum Zitat Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedCrossRef Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedCrossRef
9.
Zurück zum Zitat Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8(5):473–479PubMedCrossRef Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8(5):473–479PubMedCrossRef
10.
Zurück zum Zitat Hebbar PB, Archer TK (2003) Chromatin remodeling by nuclear receptors. Chromosoma 111(8):495–504PubMed Hebbar PB, Archer TK (2003) Chromatin remodeling by nuclear receptors. Chromosoma 111(8):495–504PubMed
11.
Zurück zum Zitat Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105(6):1242–1249PubMedCrossRef Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105(6):1242–1249PubMedCrossRef
12.
Zurück zum Zitat Jorgensen C, Sun R, Rossi JF, Costes J, Richard D, Bologna C, Sany J (1995) Expression of a multidrug resistance gene in human rheumatoid synovium. Rheumatol Int 15(2):83–86PubMedCrossRef Jorgensen C, Sun R, Rossi JF, Costes J, Richard D, Bologna C, Sany J (1995) Expression of a multidrug resistance gene in human rheumatoid synovium. Rheumatol Int 15(2):83–86PubMedCrossRef
13.
Zurück zum Zitat Lee CG, Gottesman MM (1998) HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 101(2):287–288PubMedCrossRef Lee CG, Gottesman MM (1998) HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 101(2):287–288PubMedCrossRef
14.
Zurück zum Zitat Levy AS, Cunningham-Rundles S, Mazza B, Simm M, Gorlick R, Bussel J (2002) High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol 118(3):836–838PubMedCrossRef Levy AS, Cunningham-Rundles S, Mazza B, Simm M, Gorlick R, Bussel J (2002) High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol 118(3):836–838PubMedCrossRef
15.
Zurück zum Zitat Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, Dulieu V, Bouvier M, Carli PM, Tavernier C (1996) Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 35(3):430–435PubMed Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, Dulieu V, Bouvier M, Carli PM, Tavernier C (1996) Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 35(3):430–435PubMed
16.
Zurück zum Zitat McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20(4):435–459PubMedCrossRef McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20(4):435–459PubMedCrossRef
17.
Zurück zum Zitat Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998) Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139(4):1789–1793PubMedCrossRef Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998) Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139(4):1789–1793PubMedCrossRef
18.
Zurück zum Zitat Montano E, Schmitz M, Blaser K, Simon HU (1996) P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 6(1):14–21PubMed Montano E, Schmitz M, Blaser K, Simon HU (1996) P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 6(1):14–21PubMed
19.
Zurück zum Zitat (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98(4):561–564 (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98(4):561–564
20.
Zurück zum Zitat Tsuruo T (1993) Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67(10):889–894 Tsuruo T (1993) Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67(10):889–894
21.
Zurück zum Zitat Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84(9):3004–3008PubMedCrossRef Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84(9):3004–3008PubMedCrossRef
22.
Zurück zum Zitat Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267(34):24248–24252PubMed Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267(34):24248–24252PubMed
23.
Zurück zum Zitat Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13(3):129–134PubMed Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13(3):129–134PubMed
24.
Zurück zum Zitat Wasilewska A, Zoch-Zwierz W (2005) Expression of glucocorticoid receptors in nephrotic children depending on total prednisone dose. J Pediatr Endocrinol Metab 18(8):799–806PubMed Wasilewska A, Zoch-Zwierz W (2005) Expression of glucocorticoid receptors in nephrotic children depending on total prednisone dose. J Pediatr Endocrinol Metab 18(8):799–806PubMed
25.
Zurück zum Zitat Wasilewska A, Zoch-Zwierz W, Tomaszewska B, Wiercinski R, Stasiak-Barmuta A (2003) Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome. Pediatr Nephrol 18(8):778–782PubMedCrossRef Wasilewska A, Zoch-Zwierz W, Tomaszewska B, Wiercinski R, Stasiak-Barmuta A (2003) Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome. Pediatr Nephrol 18(8):778–782PubMedCrossRef
Metadaten
Titel
Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids
verfasst von
Anna M. Wasilewska
Walentyna M. Zoch-Zwierz
Mirosława Pietruczuk
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe 12/2006
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-006-0177-1

Weitere Artikel der Ausgabe 12/2006

European Journal of Pediatrics 12/2006 Zur Ausgabe

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.